[Skip to Content]
[Skip to Content Landing]
September 8, 1956


JAMA. 1956;162(2):136. doi:10.1001/jama.1956.02970190052018

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  On the basis of recently published reports (Prien, E.L., and Walker, B.S.: Salicylate Therapy of Recurrent Calcium Urolithiasis, New England J. Med.253:446-451 [Sept. 15] 1955; Salicylamide and Acetylsalicylic Acid in Recurrent Urolithiasis, J.A.M.A.160:355-360 [Feb. 4] 1956), various drug companies are currently conducting an extensive mail campaign advertising their particular brand of salicylates for prevention and treatment of urinary calculi. It should be pointed out that this group of drugs was recommended for use only in the Presence of calcium-containing calculi. Their use in the management of patients with recurrent uric acid calculi is contraindicated because of the well-known property of salicylates to increase the urinary excretion of uric acid. Before beginning salicylate therapy, every effort should be made, including stone analysis, to determine the chemical nature of the calculi being formed.

First Page Preview View Large
First page PDF preview
First page PDF preview